Johnson & Johnson Vision announced the commercial launch of the iDESIGN Refractive Studio. The iDESIGN, which received FDA approval in June, uses topography-integrated, wavefront-guided technology, allowing doctors to take a precise measurement of the eye inside and out to deliver a LASIK procedure personalized to the individual patient.
The iDESIGN is approved for myopia, hyperopia, and mixed astigmatism. Additionally, it is the only available LASIK technology platform indicated for wavefront-guided monovision LASIK in presbyopic myopic patients. Ninety-six percent of patients reported a decrease in wearing glasses six months after Monovision LASIK with the Customvue System, according to a company news release.
“Johnson & Johnson Vision’s new iDESIGN Refractive Studio allows surgeons to measure the entire visual pathway and the cornea curvature to create an optical fingerprint unique to each patient’s eye,” Tom Frinzi, Worldwide President, Surgical, Johnson & Johnson Vision, said in the news release. “This represents an important milestone in LASIK where the procedure is now truly tailored to the individual. When we measure better, we can treat better.”
Five measurements are taken in a single one-click capture sequence with the iDESIGN Refractive Studio. Each treatment plan begins with a wavefront analysis to measure how light travels inside the eye, detailing the imperfections in a patient’s vision. The corneal topography scans the outside surface of the eye, measuring and analyzing tiny variations in curvature and elevation. The combination of the two measurements delivers a LASIK procedure tailored for each eye.
“The availability of the iDESIGN Refractive Studio in the U.S. is significant for both the ophthalmic and patient community,” Marc Odrich, MD, Medical Director, Refractive, Johnson & Johnson Vision and Associate Professor, University of Virginia, said in the news release. “We’re using LASIK technology that analyzes the entire eye inside and out. This allows us to take a customized approach specific to each patient’s corneal topographic data addressing the unique imperfections of that patient’s eyes. It is a further personalization of our unique technologies.”